NuProbe BDA Technology Enables Highly Sensitive Detection of Low-Level Variants for Oncology Research
03 mai 2023 10h00 HE
|
NuProbe USA Inc
Houston, May 03, 2023 (GLOBE NEWSWIRE) -- NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene fusions, and copy number...
Bio-Rad and NuProbe Enter into an Exclusive Licensing Agreement for Digital PCR Applications
07 nov. 2022 14h32 HE
|
NuProbe USA Inc
Hercules, Calif. and Houston, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and...
NuProbe Closes $50M in New Fundraising
02 juin 2022 11h30 HE
|
NuProbe USA Inc
Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life...
NuProbe Published Method for Designing Highly Multiplex PCR Primer Sets
19 avr. 2022 10h02 HE
|
NuProbe USA Inc
Houston, April 19, 2022 (GLOBE NEWSWIRE) -- NuProbe, a global genomics and molecular diagnostics company, announces its recent publication in Nature Communications describing a massively multiplexed...
NuProbe QASeq Technology Enables Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA
05 avr. 2022 10h06 HE
|
NuProbe USA Inc
Houston, April 05, 2022 (GLOBE NEWSWIRE) -- NuProbe, a global genomics and molecular diagnostics company, announced new published data in Nature Communications describing the use of Quantitative...
NuProbe Technology Showcases Quantitative PCR for Simultaneous Enrichment and Identification of Multiple Rare Variants below 0.1% VAF
18 janv. 2022 10h01 HE
|
NuProbe USA Inc
Houston, Jan. 18, 2022 (GLOBE NEWSWIRE) -- NuProbe, a genomics and molecular diagnostics company developing ultrasensitive assays for precision oncology research, published research today...